Adalimumab is indicated for the treatment of autoimmune inflammatory diseases, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, plaque psoriasis, Crohn’s disease, and ulcerative colitis. It is a fully human monoclonal antibody that specifically targets and neutralizes tumor necrosis factor-alpha (TNF-α), a central mediator of inflammation. Its key advantage is powerful and targeted suppression of inflammatory pathways, leading to rapid symptom relief, reduced disease activity, and prevention of structural damage. In clinical practice, adalimumab is widely used in patients with moderate to severe disease who have inadequate response to conventional therapies. Subcutaneous administration allows convenient long-term use, while its consistent efficacy and well-established safety profile make it a cornerstone biologic therapy in both rheumatology and gastroenterology.